Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
The main purpose of this study is to evaluate the efficacy of the study drug known as
 galcanezumab in participants with episodic migraine.
Inclusion Criteria:

 -  Have a diagnosis of episodic migraine as defined by International Headache Society
 (IHS) International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1
 or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior
 to screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 Migraine
 Headache Days (MHD).

 Exclusion Criteria:

 -  Are currently enrolled in or have participated within the last 30 days or within 5
 half-lives (whichever is longer) in a clinical trial involving an investigational
 product.

 -  Current use or prior exposure to Galcanezumab or another CGRP antibody.

 -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
 proteins, or to Galcanezumab.

 -  History of persistent daily headache, cluster headache or migraine subtypes including
 hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
 with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.